Adams Respiratory Therapeutics, Inc. (1319439) SEC Filing 10-K Annual report for the fiscal year ending Thursday, June 30, 2005

Exhibit 99.1

Adams Respiratory Therapeutics Reports
Fourth Quarter and Fiscal Year-End 2005 Results

Fiscal Year 2005 Highlights:

•		Net sales increased by $98.9 million to $160.2 million
•		Pretax income increased 126 percent to $44.4 million
•		Net income of $27.0 million; Pro forma diluted EPS of $0.95
•		Launched Mucinex DM in August 2004
•		Initiated major direct-to-consumer advertising campaign for Mucinex
•		Doubled the size of the professional sales force

CHESTER, N.J. (Sept. 19, 2005) – Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT), today announced financial results for the fourth quarter and fiscal year ended June 30, 2005.

“Fiscal 2005 was a watershed year for Adams on many fronts,” said Michael J. Valentino, president and CEO of Adams. “We launched our second product, Mucinex DM, initiated a major consumer advertising and marketing campaign for Mucinex as well as made significant strides in the quality and depth of retail distribution of the brand. In addition, we made preparations for an initial public equity offering, among other notable events,” added Valentino. In July, the Company completed a successful public offering generating more than $117 million in equity funding.

Fiscal Year 2005 Results

The Company’s net sales of $160.2 million in the 2005 fiscal year grew 161 percent from $61.3 million in fiscal year 2004. Net sales of Mucinex SE rose more than 120 percent to $117.4 million from sales of $52.9 million in the prior fiscal year, benefiting from a new direct-to-consumer advertising campaign that was initiated in November 2004. Launched in August 2004, Mucinex DM had fiscal 2005 sales of $38.3 million.

Pretax income for the fiscal year 2005 was $44.4 million, a 126 percent increase from pretax income of $19.7 million in the 2004 fiscal period.